Enoxaparin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Enoxaparin
- Enoxaparin: From Anticoagulation/Thromboprophylaxis to Thrombophilia due to Protein C Deficiency
Enoxaparin: From Anticoagulation/Thromboprophylaxis to Thrombophilia due to Protein C Deficiency
One-Sentence Summary
Enoxaparin is a low molecular weight heparin (LMWH) used for anticoagulation and thromboprophylaxis; its original indication list is not documented in this evidence pack. The TxGNN model predicts it may be effective for thrombophilia due to protein C deficiency, autosomal recessive, but currently no clinical trials and no published literature support this specific direction — this is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (original indication list is empty) |
| Predicted New Indication | Thrombophilia due to protein C deficiency, autosomal recessive |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for enoxaparin is not available in this evidence pack (flagged as a High-severity data gap). Based on the mechanistic rationale that accompanies this prediction, enoxaparin is a low molecular weight heparin (LMWH) that activates antithrombin III to inhibit factor Xa (and, more weakly, factor IIa), producing an anticoagulant effect.
Protein C deficiency is a hereditary hypercoagulable disorder: because the protein C/protein S pathway is impaired, affected patients are prone to venous thromboembolism. In clinical practice, LMWHs — including enoxaparin — are commonly used in these patients for thrombosis prophylaxis and acute treatment, including as a bridging therapy during warfarin initiation to avoid warfarin-induced skin necrosis, a known complication in protein C-deficient patients. This established clinical practice gives the high TxGNN score (0.9958) mechanistic plausibility, and is consistent with existing clinical experience.
That said, the underlying data are incomplete: the original indication list and the formal MOA field are both empty in this evidence pack, and no clinical trials or literature specific to this indication were identified. The mechanistic reasoning above should therefore be treated as supportive context rather than confirmed evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
UK Market Information
Enoxaparin currently has no marketing authorisation recorded in this evidence pack (market status: Not Marketed; 0 licences on file). No product-level authorisation details are available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack flags TFDA/SmPC-equivalent label warnings and contraindications as a Blocking data gap — this must be resolved before any safety pre-assessment (S1) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has strong mechanistic plausibility but Evidence Level L5 (no clinical trials, no literature) and a Blocking-severity gap in label warnings/contraindications mean the evidence base is currently insufficient to advance past initial screening.
To proceed, the following is needed:
- Label warnings and contraindications (currently a Blocking data gap; required before any S1 safety pre-assessment)
- Confirmed mechanism of action (MOA) documentation
- Confirmed original indication(s) and UK marketing/licensing status
- Targeted search for clinical trials or literature on enoxaparin (or LMWH class) in protein C deficiency/thrombophilia populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.